PRTG
SNDX icon

Post Resch Tallon Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Post Resch Tallon Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273K Hold
12,500
– – 0.19% 94
2026
Q1 		$302K Sell
12,500
-10,300
-45% -$224K 0.24% 75
2025
Q4 		$479K Sell
22,800
-3,000
-12% -$52.3K 0.4% 48
2025
Q3 		$397K Buy
+25,800
New +$338K 0.35% 54

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Post Resch Tallon Group's SNDX Position: Q2 2026 in Review

Post Resch Tallon Group held its Syndax Pharmaceuticals (SNDX) position steady in Q2 2026 at 12,500 shares worth $273K. The position accounts for 0.19% of the portfolio, ranked #94.

Post Resch Tallon Group first reported a position in SNDX in Q3 2025 and has held it in 4 quarters since. The position peaked at $479K in Q4 2025. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Post Resch Tallon Group held 12,500 shares of Syndax Pharmaceuticals worth $273K as of Q2 2026.
  • Post Resch Tallon Group left its Syndax Pharmaceuticals share count unchanged in Q2 2026.
  • Syndax Pharmaceuticals made up 0.19% of Post Resch Tallon Group's portfolio in Q2 2026, its #94 holding.
  • Post Resch Tallon Group first reported a position in Syndax Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Post Resch Tallon Group's Syndax Pharmaceuticals position peaked at $479K in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Post Resch Tallon Group's 13F filing for Q2 2026, filed 7 Jul 2026.